clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Serositis D012700 1 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Parotid Diseases D010305 1 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Sacroiliitis D058566 1 associated lipids
Achlorhydria D000126 1 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Pseudomyxoma Peritonei D011553 1 associated lipids
Eye Infections D015817 1 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Hypoproteinemia D007019 1 associated lipids
Myxoma D009232 1 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Empyema, Tuberculous D004654 1 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Duodenogastric Reflux D004383 2 associated lipids
Parotid Neoplasms D010307 2 associated lipids
Iritis D007500 2 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Iris Diseases D007499 2 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Discitis D015299 2 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Immunoproliferative Small Intestinal Disease D007161 2 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Hyperemesis Gravidarum D006939 2 associated lipids
Typhoid Fever D014435 2 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Diphtheria D004165 2 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Empyema, Pleural D016724 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Mastoiditis D008417 2 associated lipids
Periodontal Abscess D010508 2 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Ureteral Diseases D014515 3 associated lipids
Sporotrichosis D013174 3 associated lipids
Hernia, Hiatal D006551 3 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Ecchymosis D004438 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Paronychia D010304 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Scrub Typhus D012612 3 associated lipids
Fractures, Open D005597 3 associated lipids
Barrett Esophagus D001471 3 associated lipids
Giardiasis D005873 3 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Empyema D004653 3 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Tenosynovitis D013717 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Ergotism D004881 4 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Pleural Diseases D010995 4 associated lipids
Parotitis D010309 4 associated lipids
Psittacosis D009956 4 associated lipids
Prurigo D011536 4 associated lipids
Rodent Diseases D012376 4 associated lipids
Confusion D003221 4 associated lipids
Lymphangitis D008205 4 associated lipids
Mycetoma D008271 4 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Duodenitis D004382 4 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Cysts D003560 4 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Foot Diseases D005534 4 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Splenic Diseases D013158 5 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Van Oijen AH et al. Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies. 2000 Aliment. Pharmacol. Ther. pmid:10930892
Hurenkamp GJ et al. Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease. 2000 Aliment. Pharmacol. Ther. pmid:10930901
Lai KC et al. Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. 2000 Aliment. Pharmacol. Ther. pmid:10930902
Pilotto A et al. Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. 2000 Aliment. Pharmacol. Ther. pmid:10930903
Kihira K et al. Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. 2000 Aliment. Pharmacol. Ther. pmid:10930904
Kamada T et al. Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. 2000 Aliment. Pharmacol. Ther. pmid:10930905
Savarino V et al. OAM for cure of Helicobacter pylori infection. 2000 Aliment. Pharmacol. Ther. pmid:10930908
Perri F et al. Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? 2001 Aliment. Pharmacol. Ther. pmid:11421877
Perri F et al. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. 2001 Aliment. Pharmacol. Ther. pmid:11421878
Pilotto A et al. Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. 2001 Aliment. Pharmacol. Ther. pmid:11421879
Tepes B et al. Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer? 2001 Aliment. Pharmacol. Ther. pmid:11421880
Huang J et al. Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. 2013 Aliment. Pharmacol. Ther. pmid:24117692
Molina-Infante J et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. 2010 Aliment. Pharmacol. Ther. pmid:20180787
Gatta L et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. 2005 Aliment. Pharmacol. Ther. pmid:15963079
Chacko Y and Holtmann GJ Helicobacter pylori eradication and weight gain: has it opened a Pandora's box? 2011 Aliment. Pharmacol. Ther. pmid:21679208
Wong BC et al. Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study. 2001 Aliment. Pharmacol. Ther. pmid:11380322
Meier R et al. Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. 2001 Aliment. Pharmacol. Ther. pmid:11380323
Harb AH et al. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. 2015 Aliment. Pharmacol. Ther. pmid:26011564
Miehlke S et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. 2006 Aliment. Pharmacol. Ther. pmid:16842467
Neri M et al. Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection. 1994 Aliment. Pharmacol. Ther. pmid:7986974
Spinzi G et al. Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori. 1997 Aliment. Pharmacol. Ther. pmid:9146769
Peterson WL The role of antisecretory drugs in the treatment of Helicobacter pylori infection. 1997 Aliment. Pharmacol. Ther. pmid:9146787
Veldhuyzen Van Zanten S et al. One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. 2003 Aliment. Pharmacol. Ther. pmid:12786632
Wong BC et al. One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. 2001 Aliment. Pharmacol. Ther. pmid:11207516
Fakheri H et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. 2001 Aliment. Pharmacol. Ther. pmid:11207517
Lamouliatte H et al. Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. 1999 Aliment. Pharmacol. Ther. pmid:10571611
Nagahara A et al. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. 2001 Aliment. Pharmacol. Ther. pmid:11207518
Bardhan KD et al. Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. 2000 Aliment. Pharmacol. Ther. pmid:10632646
Cammarota G et al. Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. 2000 Aliment. Pharmacol. Ther. pmid:10632648
Gasbarrini A et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. 2000 Aliment. Pharmacol. Ther. pmid:10632649
Chan FK et al. Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. 2000 Aliment. Pharmacol. Ther. pmid:10632651
Pipkin GA et al. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. 1998 Aliment. Pharmacol. Ther. pmid:9768524
Fischbach LA et al. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. 2004 Aliment. Pharmacol. Ther. pmid:15569109
Louw JA et al. Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. 1998 Aliment. Pharmacol. Ther. pmid:9768531
Gu Q et al. Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycin. 2004 Aliment. Pharmacol. Ther. pmid:15352916
Tomita T et al. Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease. 2002 Aliment. Pharmacol. Ther. pmid:11966543
Axon AT et al. Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. 1997 Aliment. Pharmacol. Ther. pmid:9042977
Labenz J et al. One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. 1997 Aliment. Pharmacol. Ther. pmid:9042978
Labenz J et al. Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. 1997 Aliment. Pharmacol. Ther. pmid:9042979
Kim JS et al. Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer. 2002 Aliment. Pharmacol. Ther. pmid:11860410
Poon SK et al. Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. 2002 Aliment. Pharmacol. Ther. pmid:11860412
Peitz U et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. 2002 Aliment. Pharmacol. Ther. pmid:11860415
Sheu BS et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. 2002 Aliment. Pharmacol. Ther. pmid:12197847
Calvet X et al. One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. 2002 Aliment. Pharmacol. Ther. pmid:12144575
Di Caro S et al. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. 2002 Aliment. Pharmacol. Ther. pmid:11876707
Wu JC et al. Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. 2002 Aliment. Pharmacol. Ther. pmid:11876709
Basset C et al. Helicobacter pylori infection: anything new should we know? 2004 Aliment. Pharmacol. Ther. pmid:15335411
Calvet X et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. 2000 Aliment. Pharmacol. Ther. pmid:10792124
Savarino V et al. Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. 1999 Aliment. Pharmacol. Ther. pmid:9892878
Spinzi GC et al. Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. 1998 Aliment. Pharmacol. Ther. pmid:9663722
Bazzoli F et al. Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. 1998 Aliment. Pharmacol. Ther. pmid:9663723
Furuta T et al. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. 2007 Aliment. Pharmacol. Ther. pmid:17697203
Pozzato P et al. Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. 1998 Aliment. Pharmacol. Ther. pmid:9663724
Goh KL et al. Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? 1997 Aliment. Pharmacol. Ther. pmid:9663838
Kolkman JJ et al. Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. 1997 Aliment. Pharmacol. Ther. pmid:9663840
Miyaji H et al. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. 1997 Aliment. Pharmacol. Ther. pmid:9663841
Lionetti E et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. 2006 Aliment. Pharmacol. Ther. pmid:17032283
Iijima K et al. Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. 2004 Aliment. Pharmacol. Ther. pmid:15153171
Laurent J et al. A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. 2001 Aliment. Pharmacol. Ther. pmid:11683693
O'Connor HJ et al. Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? 1998 Aliment. Pharmacol. Ther. pmid:9570262
Scott BB Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. 1998 Aliment. Pharmacol. Ther. pmid:9570263
Goodgame RW et al. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. 2001 Aliment. Pharmacol. Ther. pmid:11736715
Malfertheiner P et al. Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. 2003 Aliment. Pharmacol. Ther. pmid:12752349
Gené E et al. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. 2003 Aliment. Pharmacol. Ther. pmid:12752350
Sheu BS et al. The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. 2003 Aliment. Pharmacol. Ther. pmid:12755841
Veldhuyzen Van Zanten S et al. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. 2000 Aliment. Pharmacol. Ther. pmid:11121908
Isomoto H et al. 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. 2000 Aliment. Pharmacol. Ther. pmid:11121910
Canducci F et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. 2000 Aliment. Pharmacol. Ther. pmid:11121911
Toracchio S et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. 2000 Aliment. Pharmacol. Ther. pmid:11121913
You JH et al. Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong. 2001 Aliment. Pharmacol. Ther. pmid:11421876
Gudjonsson H et al. High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. 1998 Aliment. Pharmacol. Ther. pmid:9845401
De Francesco V et al. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia. 2004 Aliment. Pharmacol. Ther. pmid:15113366
Koivisto TT et al. Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. 2004 Aliment. Pharmacol. Ther. pmid:15113368
Gisbert JP and Calvet X Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. 2011 Aliment. Pharmacol. Ther. pmid:22017749
Cammarota G et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. 2004 Aliment. Pharmacol. Ther. pmid:15043520
Pellegrini M et al. Is a long-term ranitidine-based triple therapy against Helicobacter pylori only a heritage of the past? A prospective, randomized clinicopharmacological study. 2005 Aliment. Pharmacol. Ther. pmid:16098001
Kawabata H et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. 2003 Aliment. Pharmacol. Ther. pmid:12534411
Gisbert JP et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. 2000 Aliment. Pharmacol. Ther. pmid:11012477
Catalano F et al. Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen. 2000 Aliment. Pharmacol. Ther. pmid:11012478
Gomollón F et al. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. 2000 Aliment. Pharmacol. Ther. pmid:11012479
Zanten SJ et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. 1999 Aliment. Pharmacol. Ther. pmid:10102960
Van der Wouden EJ et al. The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. 1999 Aliment. Pharmacol. Ther. pmid:10102961
Wong BC et al. Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. 1999 Aliment. Pharmacol. Ther. pmid:10102962
Xiao SD et al. High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. 1999 Aliment. Pharmacol. Ther. pmid:10102963
Liu WZ et al. Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. 1999 Aliment. Pharmacol. Ther. pmid:10102964
Huang J and Hunt RH Clarithromycin-based triple therapies. 1999 Aliment. Pharmacol. Ther. pmid:10102978
Osato MS et al. Comparative efficacy of new investigational agents against Helicobacter pylori. 2001 Aliment. Pharmacol. Ther. pmid:11284777
Fraser AG Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. 2017 Aliment. Pharmacol. Ther. pmid:28776748
Nista EC et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. 2003 Aliment. Pharmacol. Ther. pmid:12969089
Sheu BS et al. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. 2005 Aliment. Pharmacol. Ther. pmid:15691303
Wong WM et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. 2006 Aliment. Pharmacol. Ther. pmid:16423001
Klok RM et al. Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. 2002 Aliment. Pharmacol. Ther. pmid:11966514
Tsuzuki T et al. Clarithromycin increases the release of heat shock protein B from Helicobacter pylori. 2002 Aliment. Pharmacol. Ther. pmid:11966545
Feydt-Schmidt A et al. Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains in gastric biopsies from children. 2002 Aliment. Pharmacol. Ther. pmid:12452940
Isomoto H et al. High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. 2003 Aliment. Pharmacol. Ther. pmid:12848631
Gisbert JP et al. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. 2005 Aliment. Pharmacol. Ther. pmid:16268980
Ellenrieder V et al. Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. 1998 Aliment. Pharmacol. Ther. pmid:9701524
Miwa H et al. Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? 2003 Aliment. Pharmacol. Ther. pmid:12823158
Lim AG et al. Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. 1997 Aliment. Pharmacol. Ther. pmid:9218079
Zullo A et al. Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication? 2010 Aliment. Pharmacol. Ther. pmid:20518756